Feasibility of Gonorrhoea Vaccination among Men Who Have Sex with Men in England.
Mingwang Shen,Lei Zhang
DOI: https://doi.org/10.1016/s1473-3099(21)00760-x
IF: 71.421
2022-01-01
The Lancet Infectious Diseases
Abstract:Gonorrhoea infection is caused by Neisseria gonorrhoeae bacteria and is mainly transmitted through sexual contact. According to WHO estimates, 82·4 million new infections occurred worldwide among people aged 15–49 years in 2020.1WHOMulti-drug resistant gonorrhoea.https://www.who.int/news-room/fact-sheets/detail/multi-drug-resistant-gonorrhoeaDate accessed: November 24, 2021Google Scholar WHO proposed a target of a 90% reduction in gonorrhoea incidence by 2030, from a 2018 global baseline, as part of its global health sector strategy on sexually transmitted infections for 2016–21.2WHOGlobal health sector strategy on sexually transmitted infections 2016–2021.https://www.who.int/reproductivehealth/publications/rtis/ghss-stis/en/Date: July, 2016Date accessed: November 24, 2021Google Scholar Multidrug resistance in N gonorrhoeae has increased rapidly since 2009, according to the WHO Global Gonococcal Antimicrobial Surveillance Programme, and has substantially reduced options for treatment. Various novel preventive strategies have been proposed to reduce the transmission of gonorrhoea,3Zhang L Regan DG Chow EPF et al.Neisseria gonorrhoeae transmission among men who have sex with men: an anatomical site-specific mathematical model evaluating the potential preventive impact of mouthwash.Sex Transm Dis. 2017; 44: 586-592Google Scholar and vaccination has been identified as a priority option.4Unemo M Bradshaw CS Hocking JS et al.Sexually transmitted infections: challenges ahead.Lancet Infect Dis. 2017; 17: e235-e279Google Scholar One existing vaccine, designed to protect against meningococcal disease caused by Neisseria meningitidis (the four-component serogroup B meningococcal [4CMenB] vaccine), was found to have potential cross-protection against N gonorrhoeae, and human clinical trials of 4CMenB against N gonorrhoeae are underway.5Haese EC Thai VC Kahler CM Vaccine candidates for the control and prevention of the sexually transmitted disease gonorrhea.Vaccines (Basel). 2021; 9: 804Google Scholar Modelling the theoretical impact and cost-effectiveness of vaccines against sexually transmitted infections (STIs), including gonorrhoea, was outlined as one of nine priority action areas in WHO's global roadmap for advancing STI vaccine development.6Gottlieb SL Deal CD Giersing B et al.The global roadmap for advancing development of vaccines against sexually transmitted infections: update and next steps.Vaccine. 2016; 34: 2939-2947Google ScholarIn The Lancet Infectious Diseases, Whittles and colleagues7Whittles LK Didelot X White PJ Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.Lancet Infect Dis. 2022; (published online April 12.)https://doi.org/10.1016/S1473-3099(21)00744-1Google Scholar report on their assessment of the potential cost-effectiveness of 4CMenB vaccination against gonorrhoea among men who have sex with men (MSM) in England, based on a dynamic-transmission model. This study is the first economic evaluation of a novel gonorrhoea vaccine to use a dynamic-transmission model, rather than the static decision tree or Markov model,8Régnier SA Huels J Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model.Hum Vaccin Immunother. 2014; 10: 3737-3745Google Scholar to account for the impact of vaccination on future incidence rates. Notably, the results suggested that gonorrhoea vaccination for MSM using the 4CMenB vaccine in sexual health clinics in England was likely to be cost-effective. The recommended vaccination-according-to-risk (VaR) strategy, which involves vaccinating MSM attending clinics who have a gonorrhoea diagnosis or who report having more than five sexual partners per years, represents a valuable strategy in light of the health-economic analysis of gonorrhoea vaccination.The study's finding that 4CMenB vaccination for N gonorrhoeae in MSM would be cost-saving is based on the assumption that the 4CMenB vaccine would be priced similarly to its current UK National Health Service price for use against N meningitidis, and have an efficacy against N gonorrhoea similar to that against N meningitidis (around 31%). Several questions remained to be addressed. First, empirical human clinical trials would be required to determine the actual vaccine efficacy of 4CMenB, although the existing literature suggests that 4CMenB as a vaccine for N gonorrhoeae would be biologically feasible (figure). Second, whether MSM will widely accept the 4CMenB vaccine, given a relatively low efficacy, needs to be considered. Integrating the proposed vaccine into the existing state-sponsored insurance scheme would be a good option to ensure the cost of the vaccine would not hinder the rollout of the vaccination strategy. Third, pilot studies are necessary to verify the feasibility of the VaR approach. One of the main challenges is identifying high-risk MSM accurately using behavioural questionnaires or other risk-assessment tools before vaccination.9Bao Y Medland NA Fairley CK et al.Predicting the diagnosis of HIV and sexually transmitted infections among men who have sex with men using machine learning approaches.J Infect. 2021; 82: 48-59Google Scholar Fourth, vaccination should not replace other primary prevention measures (eg, condom use), and the potential increase in high-risk sexual behaviour due to risk compensation after vaccination should be monitored. Fifth, generalising the findings to other populations (eg, heterosexual population) and to settings in lower-income countries where screening for gonorrhoea is not a routine practice will require further investigation.Achieving WHO's 2030 target of reducing gonorrhoea incidence by 90% is subject to challenges. However, even a partially protective vaccine could still prevent a substantial proportion of high-risk individuals from gonorrhoea infection and hence further rounds of transmission.10Whittles LK White PJ Didelot X Assessment of the potential of vaccination to combat antibiotic resistance in gonorrhea: a modeling analysis to determine preferred product characteristics.Clin Infect Dis. 2020; 71: 1912-1919Google Scholar When infections do occur, people who have been vaccinated might still have a reduced within-host load of N gonorrhoeae and these infections might be more susceptible to antibiotic treatments than those in unvaccinated people. Policy makers should consider the 4CMenB vaccine as a potential option for gonorrhoea prevention and control in the effort of achieving the 2030 target before a more effective approach becomes readily available.Whittles and colleagues' study7Whittles LK Didelot X White PJ Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.Lancet Infect Dis. 2022; (published online April 12.)https://doi.org/10.1016/S1473-3099(21)00744-1Google Scholar evaluated the population effects and cost-effectiveness of four gonorrhoea vaccination strategies with varying vaccine efficacy, duration of protection, levels of vaccine uptake, and sexual behaviour in MSM based on a dynamic model. The key message of the study is that vaccination using the 4CMenB vaccine according to the risk of the targeted MSM population is likely to be cost-effective, even if the vaccine were to have a relatively low efficacy and a short duration of protection. Such a strategy should be recommended and rolled out in a high-income country setting such as England. Gonorrhoea infection is caused by Neisseria gonorrhoeae bacteria and is mainly transmitted through sexual contact. According to WHO estimates, 82·4 million new infections occurred worldwide among people aged 15–49 years in 2020.1WHOMulti-drug resistant gonorrhoea.https://www.who.int/news-room/fact-sheets/detail/multi-drug-resistant-gonorrhoeaDate accessed: November 24, 2021Google Scholar WHO proposed a target of a 90% reduction in gonorrhoea incidence by 2030, from a 2018 global baseline, as part of its global health sector strategy on sexually transmitted infections for 2016–21.2WHOGlobal health sector strategy on sexually transmitted infections 2016–2021.https://www.who.int/reproductivehealth/publications/rtis/ghss-stis/en/Date: July, 2016Date accessed: November 24, 2021Google Scholar Multidrug resistance in N gonorrhoeae has increased rapidly since 2009, according to the WHO Global Gonococcal Antimicrobial Surveillance Programme, and has substantially reduced options for treatment. Various novel preventive strategies have been proposed to reduce the transmission of gonorrhoea,3Zhang L Regan DG Chow EPF et al.Neisseria gonorrhoeae transmission among men who have sex with men: an anatomical site-specific mathematical model evaluating the potential preventive impact of mouthwash.Sex Transm Dis. 2017; 44: 586-592Google Scholar and vaccination has been identified as a priority option.4Unemo M Bradshaw CS Hocking JS et al.Sexually transmitted infections: challenges ahead.Lancet Infect Dis. 2017; 17: e235-e279Google Scholar One existing vaccine, designed to protect against meningococcal disease caused by Neisseria meningitidis (the four-component serogroup B meningococcal [4CMenB] vaccine), was found to have potential cross-protection against N gonorrhoeae, and human clinical trials of 4CMenB against N gonorrhoeae are underway.5Haese EC Thai VC Kahler CM Vaccine candidates for the control and prevention of the sexually transmitted disease gonorrhea.Vaccines (Basel). 2021; 9: 804Google Scholar Modelling the theoretical impact and cost-effectiveness of vaccines against sexually transmitted infections (STIs), including gonorrhoea, was outlined as one of nine priority action areas in WHO's global roadmap for advancing STI vaccine development.6Gottlieb SL Deal CD Giersing B et al.The global roadmap for advancing development of vaccines against sexually transmitted infections: update and next steps.Vaccine. 2016; 34: 2939-2947Google Scholar In The Lancet Infectious Diseases, Whittles and colleagues7Whittles LK Didelot X White PJ Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.Lancet Infect Dis. 2022; (published online April 12.)https://doi.org/10.1016/S1473-3099(21)00744-1Google Scholar report on their assessment of the potential cost-effectiveness of 4CMenB vaccination against gonorrhoea among men who have sex with men (MSM) in England, based on a dynamic-transmission model. This study is the first economic evaluation of a novel gonorrhoea vaccine to use a dynamic-transmission model, rather than the static decision tree or Markov model,8Régnier SA Huels J Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model.Hum Vaccin Immunother. 2014; 10: 3737-3745Google Scholar to account for the impact of vaccination on future incidence rates. Notably, the results suggested that gonorrhoea vaccination for MSM using the 4CMenB vaccine in sexual health clinics in England was likely to be cost-effective. The recommended vaccination-according-to-risk (VaR) strategy, which involves vaccinating MSM attending clinics who have a gonorrhoea diagnosis or who report having more than five sexual partners per years, represents a valuable strategy in light of the health-economic analysis of gonorrhoea vaccination. The study's finding that 4CMenB vaccination for N gonorrhoeae in MSM would be cost-saving is based on the assumption that the 4CMenB vaccine would be priced similarly to its current UK National Health Service price for use against N meningitidis, and have an efficacy against N gonorrhoea similar to that against N meningitidis (around 31%). Several questions remained to be addressed. First, empirical human clinical trials would be required to determine the actual vaccine efficacy of 4CMenB, although the existing literature suggests that 4CMenB as a vaccine for N gonorrhoeae would be biologically feasible (figure). Second, whether MSM will widely accept the 4CMenB vaccine, given a relatively low efficacy, needs to be considered. Integrating the proposed vaccine into the existing state-sponsored insurance scheme would be a good option to ensure the cost of the vaccine would not hinder the rollout of the vaccination strategy. Third, pilot studies are necessary to verify the feasibility of the VaR approach. One of the main challenges is identifying high-risk MSM accurately using behavioural questionnaires or other risk-assessment tools before vaccination.9Bao Y Medland NA Fairley CK et al.Predicting the diagnosis of HIV and sexually transmitted infections among men who have sex with men using machine learning approaches.J Infect. 2021; 82: 48-59Google Scholar Fourth, vaccination should not replace other primary prevention measures (eg, condom use), and the potential increase in high-risk sexual behaviour due to risk compensation after vaccination should be monitored. Fifth, generalising the findings to other populations (eg, heterosexual population) and to settings in lower-income countries where screening for gonorrhoea is not a routine practice will require further investigation. Achieving WHO's 2030 target of reducing gonorrhoea incidence by 90% is subject to challenges. However, even a partially protective vaccine could still prevent a substantial proportion of high-risk individuals from gonorrhoea infection and hence further rounds of transmission.10Whittles LK White PJ Didelot X Assessment of the potential of vaccination to combat antibiotic resistance in gonorrhea: a modeling analysis to determine preferred product characteristics.Clin Infect Dis. 2020; 71: 1912-1919Google Scholar When infections do occur, people who have been vaccinated might still have a reduced within-host load of N gonorrhoeae and these infections might be more susceptible to antibiotic treatments than those in unvaccinated people. Policy makers should consider the 4CMenB vaccine as a potential option for gonorrhoea prevention and control in the effort of achieving the 2030 target before a more effective approach becomes readily available. Whittles and colleagues' study7Whittles LK Didelot X White PJ Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.Lancet Infect Dis. 2022; (published online April 12.)https://doi.org/10.1016/S1473-3099(21)00744-1Google Scholar evaluated the population effects and cost-effectiveness of four gonorrhoea vaccination strategies with varying vaccine efficacy, duration of protection, levels of vaccine uptake, and sexual behaviour in MSM based on a dynamic model. The key message of the study is that vaccination using the 4CMenB vaccine according to the risk of the targeted MSM population is likely to be cost-effective, even if the vaccine were to have a relatively low efficacy and a short duration of protection. Such a strategy should be recommended and rolled out in a high-income country setting such as England. We declare no competing interests. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysisWe recommend that vaccination of MSM against gonorrhoea according to risk in sexual health clinics in England with the 4CMenB vaccine be considered. Development of gonorrhoea-specific vaccines should prioritise maximising efficacy over duration of protection. Full-Text PDF Open Access